Sarcopenia, frequently defined as an absolute muscle mass \<2 s.d. below the healthy young adult mean ([@bib5]), is associated with aging, inactivity and with a series of chronic diseases, including chronic renal failure, chronic obstructive pulmonary disease and cancer. Sarcopenia associates with poor physical function and nosocomial infections in non-cancer populations ([@bib16]; [@bib7]). Computed tomography (CT) imaging, as routinely conducted in oncology, provides a means to precisely quantify skeletal muscle ([@bib14]; [@bib12]; [@bib3]). Recently, it has been revealed that sarcopenia in cancer patients is associated with treatment toxicity, poor functional status and decreased survival ([@bib19], [@bib18], [@bib17]; [@bib1]; [@bib22]).

The numerous poor outcomes associated with sarcopenia (survival, infection, length of hospital stay, treatment toxicity, physical disability) suggest that a sarcopenic individual is generally unfit or poorly equipped to deal with stress or disease. This led us to speculate that sarcopenic individuals may have difficulty in the context of a major surgical intervention. Because infectious complications during hospitalisation have been documented in non-cancer patients with sarcopenia ([@bib16]; [@bib7]) and because muscle function is central to physical function, we conjectured that sarcopenic patients may have a longer stay in hospital, and will be less likely to be discharged home and more likely to require inpatient rehabilitation care, following a major oncologic surgery. The aim of this study was to test for an association between sarcopenia and these outcomes, by means of a review of Administrative Health Data (hospital discharge abstracts including information recorded using International Classification of Disease (ICD) 10 codes).

Materials and methods
=====================

Patient population
------------------

Ethical approval was obtained from the Alberta Cancer Research Ethics Board. Our candidate population for this study was colorectal cancer patients undergoing primary tumour resection. The patient population (*n*=234) was a consecutive cohort of Edmonton, Alberta, Canada residents with stage II--IV colorectal cancer (ICD-O codes: C18-C20 excluding appendix cancer (C18.1)) who underwent a colorectal procedure (segmental or partial colectomy, hemicolectomy, subtotal or total colectomy, sigmoid colon resection, anterior resection or abdominoperineal resection) between April 1 2002 and March 31 2006. Patients were identified by a search of the Alberta Cancer Registry, which codes primary cancers in the province of Alberta by site, morphology, clinical and demographic information. Registry records were linked with hospital discharge abstracts including information on diagnoses, procedures and outcomes using ICD-10 codes. Age, sex, cancer stage (American Joint Committee on Cancer, 7th edition), tumour site, date of surgery were obtained from the Alberta Cancer Registry. Height and weight were abstracted from records of routine clinical nutritional screening collected during consultations with the oncologist and were used to calculate the common anthropometric descriptor, body mass index (BMI).

Computed tomography image analysis
----------------------------------

Computed tomography scans taken for planning surgery were chosen; they were taken on average 31 days prior to surgery. Images were retrieved from digital storage in the Picture Archiving and Communication System. Computed tomography image analysis (Slice-O-Matic V4.3 software (Tomovision, Montreal, Canada)), was performed as described previously ([@bib14]). Briefly, total skeletal muscle and adipose tissue surface area (cm^2^) were evaluated on a single image at the third lumbar vertebrae (L3) using Hounsfield unit thresholds of −29 to +150 for skeletal muscle, −150 to −50 for visceral adipose tissue and −190 to −30 for subcutaneous and intermuscular adipose tissues. Skeletal muscle and adipose tissue area at L3 is significantly related to whole-body tissue mass in healthy adults ([@bib21]) and cancer patients ([@bib14]). Tissue cross-sectional area (cm^2^) was computed by summing tissue pixels and multiplying by the pixel surface area; areas were normalised for stature (m^2^) and reported as lumbar skeletal muscle and adipose tissue index (cm^2^ m^−2^). Sarcopenia was defined using sex-specific skeletal muscle index cutpoints (\<38.5 cm^2^ m^−2^ (females) and \<52.4 cm^2^ m^−2^ (males)) based on survival in obese cancer patients ([@bib19]). These values were identified in a cancer population using a statistical test (optimal stratification) for cutpoint in relation to increased mortality. These cutoffs were accepted by an international consensus group on the diagnostic criteria for cancer cachexia ([@bib9]). The cutpoints also give clear separation of a poor survival subgroup in patients with cirrhosis ([@bib13]).

Administrative data
-------------------

Comorbidities were obtained from inpatient hospitalisation administrative data provided by the provincial Ministry of Health. This data set includes all inpatient hospitalisations that occurred in any Alberta hospital and includes up to 16 ICD-10 diagnostic codes for each hospitalisation. Comorbidities were identified using a validated Elixhauser coding algorithm available for ICD-10 codes ([@bib20]; [@bib10]). The index surgery hospital admission, direct transfers to other facilities following the index surgical admission and re-admissions to hospital within 30 days of discharge from the index surgical admission and any hospitalisations in the year prior to the surgical hospitalisation were searched for comorbidities. Binary variables indicating the presence or absence of each comorbidity were created with the exception for obesity and weight loss, which are not properly captured using administrative health data.

Obstruction and perforation were also identified using ICD-10 codes. Patients were considered to have presented with obstruction if the code K56.6 (other and unspecified intestinal obstruction) was reported in the index surgical hospital admission; patients were considered to have presented with perforation if the code K63.1 (perforation of intestine (non traumatic)) was present in the index surgical admission.

Data on infections and rehabilitation care following surgery were also identified from ICD-10 diagnostic codes from the inpatient hospitalisation administrative data as described above. We searched the index surgery hospital admission, direct transfers to other facilities following the index surgical admission and re-admissions to hospital within 30 days of discharge from the index surgical admission for ICD-10 codes indicating evidence of an infection or a requirement for rehabilitation care.

Each hospitalisation abstract also contains dates of admission and discharge, which were subtracted from one another to calculate length of stay (LOS). Decisions regarding discharge in this population reside with the individual surgeon.

Statistical analysis
--------------------

SPSS v18.0 (IBM SPSS Statistics, Ontario, Canada) was used for statistical analysis. Data are presented as mean±s.d. Two sample independent *t*-tests and *χ*^2^/Fisher Exact tests were used to test for differences in continuous and categorical variables, respectively. Univariate and multivariate logistic regression were used to assess the relationship between sarcopenia and categorical variables. All tests were two-sided and *α* was set at 0.05.

Results
=======

Patient characteristics are listed in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. One patient (0.4%) died during the index surgery hospitalisation; no other patients died during admissions related to rehabilitation or re-admissions to hospital. Body weight and composition characteristics are listed in [Table 1](#tbl1){ref-type="table"}. Body mass index prior to surgery was variable and ranged from 17.5 to 48.8 kg m^−2^; the mean BMI for this cohort was in the overweight category (28.5±5.3 kg m^−2^).

Lumbar skeletal muscle index exhibited variation in both sexes ([Figure 1](#fig1){ref-type="fig"}), with the least muscular individuals having half as much muscle as the most muscular ones. Overall, 91 patients (38.9%) were classified as sarcopenic. Sarcopenia was significantly more common in patients ⩾65 years compared with those \<65 years (48.6% *vs* 30.1%, *P*=0.004). Patients \<65 years had more muscle than those ⩾65 years (women: 43.4±5.8 cm^2^ m^−2^ *vs* 40.7±6.9 cm^2^ m^−2^, *P*=0.042; men: 57.0±8.9 cm^2^ m^−2^ *vs* 51.8±7.1 cm^2^ m^−2^, *P*\<0.001).

Several factors were associated with sarcopenia ([Table 2](#tbl2){ref-type="table"}). Individuals with sarcopenia were on average older, and had a lower BMI than those without sarcopenia; men and women were equally likely to present with sarcopenia. Several comorbidities were more common in individuals with sarcopenia compared with those without including cardiac arrythmias, diabetes, hypertension, deficiency anaemia, hypothyroidism and fluid and electrolyte disorders. Moreover, obstruction was more common in patients with sarcopenia and they were thus more likely to present for surgery on an emergency/urgent basis. Cancer stage, and tumour site were not associated with sarcopenia. Open (*vs* laparoscopic) surgical procedures and the placement of colostomy or ilieostomy were not associated with sarcopenia. There were six total coded complications (N99xx) post-procedural kidney failure, urethral stricture, post-procedural pelvic peritoneal adhesions and these were equally distributed in the sarcopenic and non-sarcopenic groups.

Outcomes
--------

The relationship between sarcopenia and infection, requirement for rehabilitation care following surgery and LOS is reported in [Table 3](#tbl3){ref-type="table"}. Overall, sarcopenia was related to these outcomes in all patients (*P*-values \<0.05). However, when examining the relationship between sarcopenia and these outcomes in younger patients only (i.e., those \<65 years), sarcopenia was not a significant predictor. Moreover, in the case of the requirement for inpatient rehabilitation care, this was almost exclusively an outcome in patients older than 65 years. Therefore, we decided to focus our analysis and results on those ⩾65 years.

Postoperative infection and inpatient rehabilitation in patients over 65 years of age
-------------------------------------------------------------------------------------

### Infections

Overall, 39 patients (16.7%) had an infection code recorded in the hospitalisation record. The following ICD-10 diagnostic codes related to infection were found: urinary tract infection (N39.0), pneumonia (J18.X), peritonitis (K65.0, K65.8), septicaemia (A41.X), infection following a procedure (T81.4), enterocolitis due to *Clostridium difficile* (A04.7) and diarrhoea and gastroenteritis of presumed infectious origin(A09)). [Figure 1A](#fig1){ref-type="fig"} shows the distribution of infection by skeletal muscle index and age. Patients with sarcopenia had an infection code recorded more frequently than those without sarcopenia (23.1% *vs* 12.6%, *P*=0.036). Sarcopenia had no relation with the rate of infection code recorded in patients \<65 years. Sarcopenic patients ⩾65 years also had infections more frequently compared with non-sarcopenic patients ⩾65 years (29.6% *vs* 8.8%, *P*=0.005). In the multiple logistic regression analysis, sarcopenia was independently predictive of postoperative infections in a multivariate analysis including sex, cancer stage and tumour site (odds ratio (OR): 4.6; 95% confidence interval (CI): 1.5--13.9) ([Table 4](#tbl4){ref-type="table"}). Age was a significant predictor of infection at the univariate level, but was not significant in any multivariate model in which sarcopenia was also included. We also assessed all of the individual major comorbidities as well as the presence of obstruction for relationship with infection. We did not find any significant relationship with infection at the univariate level. Finally, neither visceral, subcutaneous nor total lumbar adipose tissue significantly related to postoperative infection or rehabilitation.

### Need for additional rehabilitation

Excluding the patient who died in the index hospitalisation, 21 patients (9.0%) required inpatient hospitalisation for rehabilitation and 19 of those patients (90%) were ⩾65 years ([Figure 1B](#fig1){ref-type="fig"}). The following ICD-10 codes were found relating to use of inpatient rehabilitation care: convalescence following surgery or combined treatment (Z54.0, Z54.7), care involving use of rehabilitation procedures (Z50.8, Z50.9), or other physical therapy (Z50.1). Inpatient rehabilitation care occurred in the same hospital as the index surgery in 14% of cases, and in a nursing home or rehabilitation hospital in 86% of cases. Length of stay following transfer to a rehabilitation facility was 14.8±10.9 days. Inpatient rehabilitation care was more common for sarcopenic patients overall (14.3% *vs* 5.6% *P*=0.024) as well as for those ⩾65 years (24.1% *vs* 10.7%, *P*=0.06). In patients ⩾65 years, in a multivariate analysis including sex, cancer stage and tumour site, the risk of convalescent care was higher in patients with sarcopenia (OR: 3.1, 95% CI 1.04, 9.4) ([Table 2](#tbl2){ref-type="table"}). Age was a significant predictor of rehabilitation at the univariate level, but was not significant in any multivariate model in which sarcopenia was also included. Comorbidities and obstruction were not significantly related to rehabilitation care.

### Length of stay (LOS)

An accurate LOS related to recovery following colorectal cancer surgery could not be calculated for five patients who were excluded from this analysis. Four of those patients had a code in their relevant record(s), indicating they were on a waiting list for admission elsewhere (ICD-10: Z75.1), and another patient had a hip replacement during the index surgical admission. Considering the LOS of the index hospitalisation, the mean overall LOS was 11.6±7.4 days in all patients and 13.7±8.4 days in those ⩾65 years (*P*\<0.001). Patients without sarcopenia had an index hospitalisation LOS of 10.6±6.2 days compared with 13.2±8.8 days in patients with sarcopenia (*P*=0.012). In patients ⩾65 years, sarcopenic patients had a LOS of 15.7±9.8 days compared with 11.8±6.4 days for non-sarcopenic patients (*P*=0.018).

Discussion
==========

We conducted specific quantification of skeletal muscle by CT image analysis in patients admitted for colorectal cancer resection. Using this approach, we show that sarcopenia is prevalent in this population, the depletion of muscle mass is a risk factor for perioperative infection, and sarcopenia is associated with increased health service utilisation, in the form of increased LOS and requirements for prolonged rehabilitation care. This was particularly the case with older patients. Within the limitations of the use of administrative health data, it seems clear that depletion of skeletal muscle mass in an increasingly elderly population of cancer patients will have ramifications for the use of a variety of health-care services. Future prospective studies are required to confirm these results and to determine longer term outcomes and risks, the potential additional use of outpatient health services such as home care, as well as impact on quality of life and exact costs associated with sarcopenia.

Sarcopenia has been associated with reduced survival and chemotherapy treatment toxicity ([@bib19], [@bib18], [@bib17]; [@bib1]; [@bib22]). [@bib15] examined sarcopenia in relation to outcome of cancer surgery (liver resection for colorectal liver metastasis). Total psoas muscle area on computed tomography was used to assess sarcopenia, and by this criterion sarcopenia was associated with an increased risk of major postoperative complications in multivariate analysis (OR 3.12; *P*=0.02). Patients with sarcopenia also had longer hospital stays (6.6 *vs* 5.4 days; *P*=0.03) and a higher chance of an extended intensive care unit stay (\>2 days; *P*=0.004). [@bib2] did not find an association between sarcopenia and hospital LOS in 47 patients with gastroesophageal cancer patients. Further prospective studies are required to confirm and expand the findings available to date. In prospective work, additional details may be acquired, which may be related to skeletal muscle mass. For example, within the index hospitalisation, glucose control would be an interesting topic for a future study, because muscle is a quantitatively important site of glucose disposal. Post-discharge outcomes such as physical functioning, use of outpatient rehabilitation services and return to work will also be of interest.

Sarcopenia is not restricted to individuals who appear thin or wasted. Indeed, our patient population was characterised by heavy body weights with a mean BMI (28.5 kg m^−2^) in the upper end of overweight. A conventionally understood risk for poor outcomes of surgery, BMI \<18.5 kg m^−2^ (clinically underweight) is increasingly rare in contemporary populations of cancer patients. The results here are in concordance with observations in patients with gastrointestinal malignancies and non-small cell lung cancer ([@bib19]; [@bib4]) who have simultaneously heavy body weight and severe muscle depletion. Sarcopenia, as opposed to generalised overall wasting, is often an occult condition, Sarcopenia is hidden from view by a mantle of adipose tissue and it is important that it is easy to be unaware of this deterioration of the muscle mass, without the use of diagnostic imaging or some other approach (e.g., dual energy X-ray absorptiometry) for its specific detection. Computed tomography images used for planning surgery are a convenient resource to detect sarcopenia. As these images are routinely available in the clinical record, no incremental testing is needed to make the relevant assessments. The significant prevalence of sarcopenia at presentation for surgery suggests that muscle atrophy occurs prior to cancer diagnosis and surgery. Neither the point at time of onset of muscle loss nor the exact aetiology, are known. However, sarcopenia is often attributed to aging, and indeed our patients with sarcopenia were 5 years older on average. Considering cancer, the primary diagnosis, and its role in the generation of sarcopenia, the dominant effect was that of obstruction, which was significantly more common in patients with sarcopenia, whereas cancer site or stage was less important. After diagnosis and over the course of treatment, muscle loss continues. Our earlier work ([@bib11]) demonstrated the progressive increase in the rate of muscle wasting in colorectal cancer patients during the year preceding death. Sarcopenia may also potentially be explained by comorbid conditions, as several chronic diseases are characterised by wasting. Here, the sarcopenic patients had a significantly higher number of comorbidities. Sarcopenia is also a consequence of inactivity and bed rest ([@bib6]) and besides being generally more ill, sarcopenic patients had already spent more total time in hospital in the year preceding their colorectal cancer surgery, than non-sarcopenic patients. It is likely that all of the aforementioned influences contribute to the eventual development of severe muscle depletion, and their respective importance may be difficult to specifically quantify.

Ideally, cutpoints for sarcopenia should be solved within each specific patient population and BMI category (obese, overweight, normal weight, underweight). A much larger sample would be required to undertake cut point analysis by sex and by BMI. Until data are assembled in sufficient number, we note that the cutpoints used here ([@bib19]) have subsequently proven to be independent predictors of survival and treatment toxicity in cancer patients ([@bib18], [@bib17]) as well as independently predictive of survival in cirrhosis patients ([@bib13]).

Clinical research on cancer-associated muscle wasting is growing and several treatments are in development ([@bib8]). Therapeutic approaches are predicated on participation of key molecules in signalling muscle catabolism, and the hypothesis that wasting is reversible by specific interventions targeting these signals. Given the relatively long expected survival of patients referred for colorectal cancer resection, they may be a suitable candidate population for testing these approaches and the prediction that reversal of sarcopenia may confer multiple benefits to patients and the health-care system.

Conclusion
==========

Sarcopenia predicts infections, inpatient rehabilitation care and consequently a longer LOS, in colorectal cancer patients.
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###### Patient body weight and composition

                                                                            **All patients (*****n*****=234)**   **Non-sarcopenic (*****n*****=143)**   **Sarcopenic (*****n*****=91)**   ***P*****-value**
  ------------------------------------------------------------------------- ------------------------------------ -------------------------------------- --------------------------------- -------------------
  *Body weight*                                                                                                                                                                           
   BMI (kg m^−2^)[a](#t1-fn1){ref-type="fn"}                                28.5±5.3                             30.0±5.4                               26.1±4.2                          \<0.001
   BMI category, *n* (%)                                                                                                                                                                  
    Underweight                                                             1 (0.5)                              0 (0)                                  1 (1.3)                           \<0.001
    Normal weight                                                           47 (23.6)                            19 (15.4)                              28 (36.8)                          
    Overweight                                                              90 (45.2)                            53 (43.1)                              37 (48.7)                          
    Obese                                                                   61 (30.7)                            51 (41.5)                              10 (13.2)                          
                                                                                                                                                                                           
  *Body composition*                                                                                                                                                                      
   Men L3 skeletal muscle index (cm^2^ m^−2^)                               54.8±8.6                             60.3±6.7                               47.3±3.6                          \<0.001
   Women L3 skeletal muscle index (cm^2^ m^−2^)                             41.9±6.5                             45.5±4.7                               35.0±2.9                          \<0.001
   Men L3 adipose tissue index (cm^2^ m^−2^)[b](#t1-fn2){ref-type="fn"}     117.4±55.8                           130.4±56.5                             99.4±49.8                         0.002
   Women L3 adipose tissue index (cm^2^ m^−2^)[b](#t1-fn2){ref-type="fn"}   128.6±72.5                           142.3±75.6                             102.1±58.6                        0.007

Abbreviation: BMI=body mass index.

BMI was not available for 35 patients (20 non-sarcopenic and 15 sarcopenic).

Total adipose tissue index was missing for 8 female patients and 13 male patients due to subcutaneous adipose tissue being cut off from computed tomography scan field of view.

###### Demographic and clinical factors associated with sarcopenia

                                                      **All patients (*****n*****=234)**   **Non-sarcopenic (*****n*****=143)**   **Sarcopenic (*****n*****=91)**   ***P*****-value**
  --------------------------------------------------- ------------------------------------ -------------------------------------- --------------------------------- -------------------
  *Demographic*                                                                                                                                                     
   Age (years)                                        63±12                                61±11                                  66±12                             0.001
   Sex, % male                                        135 (57.7)                           78 (54.5)                              57 (62.6)                         0.22
                                                                                                                                                                     
  *Comorbidity*[a](#t2-fn1){ref-type="fn"}, n *(%)*                                                                                                                 
   Cardiac arrhythmias                                26 (11.2)                            7 (4.9)                                19 (21.1)                         \<0.001
   Hypertension                                       77 (33.0)                            38 (26.6)                              39 (43.3)                         0.008
   Chronic pulmonary disease                          11 (4.7)                             3 (2.1)                                8 (8.9)                           0.025
   Diabetes                                           39 (16.7)                            18 (12.6)                              21 (23.3)                         0.032
   Hypothyroidism                                     15 (6.4)                             5 (3.5)                                10 (11.1)                         0.021
   Deficiency anaemia                                 11 (4.7)                             3 (2.1)                                8 (8.9)                           0.025
   Fluid and electrolyte disorders                    13 (5.6)                             5 (3.5)                                8 (8.9)                           0.081
   Days in hospital in the year prior to surgery      1.7±5.2                              0.99±2.5                               2.8±7.6                           0.029
                                                                                                                                                                     
  *Cancer*                                                                                                                                                          
   Primary tumour site, *n* (%)                                                                                                                                      
    Colon                                             137 (58.5)                           83 (58.0)                              54 (59.3)                          
    Rectosigmoid junction                             27 (11.5)                            16 (11.2)                              11 (12.1)                          
    Rectum                                            70 (29.9)                            44 (30.8)                              26 (28.6)                         0.93
   Cancer stage, *n* (%)                                                                                                                                            
    Stage II                                          74 (31.6)                            48 (33.6)                              26 (28.6)                          
    Stage III                                         83 (35.5)                            52 (36.4)                              31 (34.1)                          
    Stage IV                                          77 (32.9)                            43 (30.1)                              34 (37.4)                         0.49
   Perforation, *n* (%)                               5 (2.1)                              2 (1.4)                                3 (3.3)                           0.380
   Obstruction, *n* (%)                               28 (12.0)                            11 (7.7)                               17 (18.7)                         0.012
   Readmission within 30 days, *n* (%)                14 (6.0)                             10 (7.0)                               4 (4.4)                           0.414
   Colostomy or ileostomy, *n* (%)                    29 (12.4)                            16 (11.2)                              13 (14.3)                         0.483
   Emergency procedure, *n* (%)                       83 (35.5)                            43 (30.1)                              40 (44.0)                         0.022
   Laparoscopic procedure, *n* (%)                    18 (7.7)                             12 (8.4)                               6 (6.6)                           0.615

Less than 5% of patients had the following conditions: valvular disease, pulmonary circulation disorders, peripheral vascular disease, congestive heart failure, paralysis, renal failure, liver disease, peptic ulcer disease, AIDS, rheumatoid arthritis, coagulopathy, blood loss anaemia, depression, alcohol abuse, drug abuse, psychosis. Hypertension and hypertension with complications were combined. Diabetes and diabetes with complications were combined.

###### The relationship between sarcopenia and outcomes of hospitalisation

                                                                                          **All patients (*****n*****=234)**             **Non-sarcopenic (*****n*****=143)**   **Sarcopenic (*****n*****=91)**   ***P*****-value**
  --------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------- --------------------------------- -------------------
  Infection ICD-10 code (⩾1) recorded (*n* (%))                                           39 (16.7)                                      18 (12.6)                              21 (23.1)                         0.036
  Inpatient rehabilitation care code (⩾1) recorded (*n* (%))[a](#t3-fn1){ref-type="fn"}   21 (9.0)                                       8 (5.6)                                13 (14.3)                         0.024
  Index admission length of stay (days)                                                   11.6±7.4                                       10.6±6.2                               13.2±8.8                          0.012
  Mean length of total stay in hospital (days)[b](#t3-fn2){ref-type="fn"}                 13.7±11.8                                      12.3±9.8                               15.9±14.2                         0.038
                                                                                                                                                                                                                   
                                                                                          **All patients ⩾65 years (*****n*****=111)**   **Non-sarcopenic (*****n*****=57)**    **Sarcopenic (*****n*****=54)**   ***P*****-value**
  Infection ICD-10 code (⩾1) recorded (*n* (%))                                           21 (18.9)                                      5 (8.8)                                16 (29.6)                         0.005
  Inpatient rehabilitation care code (⩾1) recorded (*n* (%))[a](#t3-fn1){ref-type="fn"}   19 (17.1)                                      6 (10.7)                               13 (24.1)                         0.064
  Index admission length of stay                                                          13.7±8.4                                       11.8±6.4                               15.7±9.8                          0.018
  Mean length of stay in hospital (days)[b](#t3-fn2){ref-type="fn"}                       16.5±13.6                                      13.1±8.3                               20.2±16.9                         0.008

Abbreviation: ICD=International Classification of Disease.

One patient who died in hospital was not considered in the analysis for inpatient rehabilitation care.

Five patients were ineligible for this analysis as outlined in the Results section.

###### Multivariate logistic regression for predictors of inpatient rehabilitation/convalescent care and infection in patients over 65 years of age undergoing colorectal cancer surgery

                                        **Infection**          **Convalescent/rehabilitation care**                                                                                                                             
  ------------------------------ ---------------------------- -------------------------------------- -------------------------- ------------------- ---------------------------- ------------------- -------------------------- -------------------
                                  **Unadjusted OR (95% CI)**            ***P*****-value**             **Adjusted OR (95% CI)**   ***P*****-value**   **Unadjusted OR (95% CI)**   ***P*****-value**   **Adjusted OR (95% CI)**   ***P*****-value**
  *Sarcopenia*                                                                                                                                                                                                                  
   No                                        1.0                                                                1.0                                             1.0                                             1.0                       
   Yes                                 4.4 (1.5, 13.0)                        0.008                       4.6 (1.5, 13.9)              0.007              2.6 (0.92, 7.6)               0.070             3.1 (1.04, 9.4)              0.043
                                                                                                                                                                                                                                          
  *Sex*                                                                                                                                                                                                                         
   Female                                    1.0                                                                1.0                                             1.0                                             1.0                       
   Male                                1.1 (0.43, 2.8)                         0.84                       0.99 (0.36, 2.7)             0.98               0.68 (0.25, 1.8)              0.45              0.65 (0.22, 1.9)             0.43
                                                                                                                                                                                                                                          
  *Cancer stage*                                                                                                                                                                                                                
   II                                        1.0                                                                1.0                                             1.0                                             1.0                       
   III                                 0.63 (0.21, 1.9)                                                   0.63 (0.20, 2.0)                                1.5 (0.46, 4.6)                                 1.6 (0.48, 5.5)                 
   IV                                  0.45 (0.14, 1.5)                        0.42                       0.42 (0.12, 1.5)             0.40               0.60 (0.16, 2.4)              0.40              0.74 (0.18, 3.1)             0.48
                                                                                                                                                                                                                                          
  *Primary tumour site*                                                                                                                                                                                                         
   Colon/rectosigmoid junction               1.0                                                                1.0                                             1.0                                             1.0                       
   Rectum                              1.2 (0.43, 3.6)                         0.67                       1.1 (0.37, 3.5)              0.82               2.6 (0.92, 7.3)               0.073             2.7 (0.88, 8.1)              0.082

Abbreviations: CI=confidence interval; OR=odds ratio.
